Baxter expands Kuros' orthobiologics pact
This article was originally published in Clinica
Executive Summary
Baxter has gained exclusive worldwide rights to develop and market a range of hard and soft tissue repair products that incorporate a combination of its Tisseel fibrin sealant and the proprietary biologics and fibrin binding know-how of Swiss biomedical firm Kuros Biosurgery.